NSN 6505-01-690-4043 · NIIN 016904043 · FSC 6505
NO DASHES 6505016904043
In Stock
INFLIXIMAB FOR INJECTION
Drugs and Biologicals
Technical characteristics
5 rows
Straight from the federal item record. Entries the record leaves empty are shown empty — nothing is filled in on its behalf.
| MRC | Requirement | Value |
|---|---|---|
| FEAT | SPECIAL FEATURES | INLFLECTRA IS A TISSUE NECROSIS FACTOR (TNF) BLOCKER INDICATED FOR CROHN'S DISEASE TO REDUCE THE SIGNS AND SYMPTOMS AND INDUCING AND MAINTAINING CLINICAL REMISSION IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPY; THE LYOPHILIZED FORMULATION NEEDS TO BE RECONSTITUTED WITH 10 ML OF STERILE WATER PRIOR TO USE; PACKAGED AS 100 MG; INTENDED FOR INTRAVENOUS INFUSION ONLY; SINGLE-USE VIAL; DISCARD UNUSED PORTION; CONCENTRATION OF FINAL SOLUTION 10MG/1ML; MUST BE REFRIGERATED AT 2 C TO 8 C (36 F TO 46 F); DO NOT USE INFLECTRA BEYOND THE EXPIRATION DATE; THIS PRODUCT CONTAINS NO PRESERVATIVE. |
| CQCT | PRIMARY CONTAINER TYPE | VIAL |
| CSGS | ADMINISTRATION | INTRAVENOUS INFUSION |
| CXCY | PART NAME ASSIGNED BY CONTROLLING AGENCY | INFLIXIMAB FOR INJECTION, 100MG PER VIAL |
| CRLK | PRIMARY CONTAINER CONTENT QUANTITY | MILLILITERS AFTER RECONSTITUTION 10.0 |